Adamis Pharmaceuticals has received a patent for TeloB-VAX technology, developed for cell-based cancer vaccines in Europe. The technology provides a method — somatic transgene immunization (STI) — to deliver a nucleic acid molecule such as DNA vaccine into B cells (a cell of the immune system).
PBR